April 23, 2010 (FinancialWire) — Myriad Genetics, Inc. (NASDAQ: MYGN) said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man's risk of prostate cancer recurrence after radical prostatectomy.

The PTEN gene is a tumor suppressor gene, which mutates in a large number of cancers. Details of the study were presented at the 2010 meeting of the American Association for Cancer Research in Washington D.C. The presentation was entitled: "PTEN Expression Predicts Biochemical Recurrence in Prostate Cancer."

The study examined prostate tumor tissue from 132 patients for which five-year follow-up data were available following prostatectomy surgery. PTEN protein expression was determined by immunohistochemisty, and was predictive of biochemical recurrence of prostate cancer in this patient group.

In addition, the analysis of the PTEN gene and the loss of PTEN function was predictive of patient survival outcome at a statistically significant level after adjusting for tumor stage, suggesting that PTEN status provides additional prognostic information not otherwise available to physicians.

Myriad Genetics, Inc. is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine products.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [bsnnssb] [dvcmntnmc] [hlthcrdp]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.